Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Anal cancer
Stage/Subtype:  stage IV anal cancer
Country:  U.S.A.
Trial Type:  Treatment
Results 1-15 of 15 for your search:
Start Over
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
Phase I/II Study of PDR001 in Patients With Advanced Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CPDR001X2101, NCI-2015-00577, 2014-003929-17, NCT02404441
Cisplatin and Fluorouracil Compared with Carboplatin and Paclitaxel in Treating Patients with Inoperable Locally Recurrent or Metastatic Anal Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: EA2133, NCI-2015-00771, 13/LO/1463, 2013-001949-13, 3847, CCR 3847, InterAACT CCR 3847, NCT02051868
Phase 2 Study of ADXS11-001 in Subjects With Carcinoma of the Anorectal Canal
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: ADXS001-06, NCI-2015-01897, NCT02399813
Nivolumab and Synthetic Long E6/E7 Peptides Vaccine HPV-01 in Treating Patients with Recurrent or Metastatic Incurable HPV-16-Positive Solid Tumors
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2014-1047, NCI-2015-01004, NCT02426892
Stereotactic Radiosurgery in Treating Patients with Oligometastatic Disease
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-027, NCI-2014-01952, REN13120042, UPCI #10-027, NCT01345539
Stereotactic Radiosurgery in Treating Patients with Oligo-Recurrent Disease
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-028, NCI-2014-01953, REN13120040, UPCI# 10-028, NCT01345552
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 3475-158, NCI-2015-02278, 163196, 2015-002067-41, NCT02628067
Pembrolizumab in Treating Patients with Refractory Metastatic Anal Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 16-301, NCI-2016-01563, NCT02919969
High-Dose-Rate Brachytherapy and Chemotherapy in Treating Patients with Locally Recurrent or Residual Rectal or Anal Cancer Undergoing Non-operative Management
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 14-104, NCI-2014-01649, NCT02199236
A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: D4190C00010, NCI-2014-02609, NCT02261220
Alisertib and Combination Chemotherapy in Treating Patients with Gastrointestinal Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9824, NCI-2014-02475, VICC GI1536, NCT02319018
T-Cell Receptor Gene Therapy Targeting HPV-16 E7 with or without Pembrolizumab in Treating Patients with Metastatic, Refractory, or Recurrent HPV-Related Cancers
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 to 60
Trial IDs: 16-C-0154, NCI-2016-01170, P152617, NCT02858310
Radiation Therapy, Fluorouracil, and Mitomycin in Treating Patients with Stage I-IIIB Anal Cancer
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-075, NCI-2013-01820, NCT01858025
Ribavirin in Treating Patients with Recurrent or Metastatic Human Papillomavirus-Related Malignancies
Status: Active
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: 14-211, NCI-2014-02540, NCT02308241
Start Over